News

News stories

Bricks being laid at SITraN

New chapter in Sheffield’s world-renowned neuroscience research

New development at the University of Sheffield will double the research capacity of the world-leading research facility, accelerating the progress of breakthrough treatments for neurological diseases such as Parkinson's, Alzheimer's and 51²è¹Ý¶ù.

Image of motor neurones

Sheffield scientist awarded prestigious prize for groundbreaking 51²è¹Ý¶ù research

Dr Johnathan Cooper-Knock from the University of Sheffield is one of eight outstanding scientists nationwide to receive the 2025 Lister Award in recognition of his pioneering 51²è¹Ý¶ù research.
Professor Dame Pamela Shaw
Professor Dame Pamela Shaw

World-renowned 51²è¹Ý¶ù researcher and clinician says making research easier to understand, and showing why it matters, is vital

One of the world’s leading scientists on motor neurone disease (51²è¹Ý¶ù) and other neurological diseases says making complex research more accessible and understandable is vital to show progress is being made at developing treatments for the conditions.
A wide-angle shot of a large gathering of walkers at the start of the Big Walk 2025, holding up a Big Walk banner

Smiles for miles at the Big Walk 2025 - well done to everyone involved!

The famed Sheffield community fundraising event was a huge success once again. Over 400 walkers and volunteers covered thousands of miles between them, supporting life-changing neurological disease research at the University.
Architect's rendering of proposed new SITraN sister facility

Garfield Weston grant backs SITraN expansion

A newly made grant from the Garfield Weston Foundation has added to multiple other donations and fundraising drives, meaning planned expansion work can now go ahead at the world-leading Sheffield Institute of Translational Neuroscience.
Image of motor neurones

Groundbreaking EXPERTS-ALS study for 51²è¹Ý¶ù treatments

The EXPErimental medicine Route To Success in ALS (EXPERTS-ALS) project aims to rapidly screen potential drugs for evidence that they can slow down damage to the nervous system occurring in people with motor neuron disease
woman using laptop on knee

People living with 51²è¹Ý¶ù given a voice in research with new digital tool

People living with motor neuron disease (51²è¹Ý¶ù) will have more opportunities to participate in groundbreaking research, thanks to a new digital platform designed to accelerate the search for a cure for the debilitating disease.

Dementia patient

New clue in understanding increased Alzheimer’s risk

Scientists have discovered a new piece of the puzzle in understanding why some people are more susceptible to Alzheimer’s disease.
Pam Shaw in front of SITraN

Comment: A devastating setback for 51²è¹Ý¶ù research: Why NICE needs to reconsider its approach to tofersen

Professor Dame Pamela Shaw, Director of the Sheffield Institute for Translational Neuroscience, discusses NICE's refusal to classify the 51²è¹Ý¶ù drug tofersen, as a treatment for a highly specialised condition, rather than just a standard drug.